RxDoctor Payments DataLook up a doctor →

Leslie Storey, MD

MOHS-Micrographic Surgery · Fresno, CANPI 1043313133

Payments from drug & device makers

$10,637in general payments, 2019–2025

Across 639 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$940
  • Novartis$785
  • LEO Pharma Inc.$755
  • Lilly USA, LLC$755
  • Sun Pharmaceutical Industries Inc.$613
  • plus $4K from 26 others

What the payments were for

  • Food & beverage$10,13595%
  • Education$5035%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,637 in reported general payments places this provider in the 80th percentile of 144 mohs-micrographic surgery providers in California.

See all mohs-micrographic surgery providers in California

Medicare billing

Part B allowed, 2024
$3,479,621
Medicare patients
4,712
Services billed
41,919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab25$332,225
Dupixent PenDupilumab79$293,666
Humira(Cf) PenAdalimumab12$176,459
OtezlaApremilast16$111,215
Taltz AutoinjectorIxekizumab16$111,082
EnbrelEtanercept13$47,776
AdbryTralokinumab-Ldrm11$40,914
Dupixent SyringeDupilumab11$40,442
OpzeluraRuxolitinib Phosphate14$27,014
Doxycycline Hyclate455$6,496
Metronidazole116$6,085
Ivermectin18$5,391
Fluorouracil82$5,388
Ketoconazole313$4,984
Clobetasol Propionate90$3,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$940$332,22525 claims
AmgenOtezla, Enbrel$186$158,99229 claims
LEO Pharma Inc.Adbry$755$40,91411 claims
Incyte CorporationOpzelura$535$27,01414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 144 mohs-micrographic surgery providers in California.

Other mohs-micrographic surgery in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →